

Chinese Herbal Formulae and Non-alcoholic Fatty Liver Disease

*A preliminary investigation in an
experimental animal model*

Christine (Hyun Jin) Kim BHealth Sci (TCM)

A thesis submitted as partial requirement for the degree of
Master of Science by Research

Faculty of Science

University of Technology, Sydney

May 2009

“The Gods have put diagnosis before therapy- man must put careful observation and interpretation before diagnosis.”


Franz Volhard (1876-1950)

CERTIFICATE OF AUTHORSHIP/ ORIGINALITY

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Signature of Student



Abstract

Background: Non-alcoholic Fatty Liver Disease (NAFLD) embodies the hepatic manifestation of metabolic syndrome, commonly associated with obesity, hyperinsulinaemia, peripheral insulin resistance, diabetes, hypertension, hypercholesterolaemia and hypertriglyceridaemia (Sanyal, 2002). NAFLD is recently conceded to be a global epidemic burden, being ranked as the second leading cause of preventative death (Younossi, 2008). Since the pathogenesis of NAFLD remains controversial, no established pharmacological agent has been developed that effectively targets or prevents excessive fat accumulation in the hepatocytes and, as a result, current treatments are primarily symptomatic. Chinese herbal medicine has become a growing focus for Western medical research in the quest for more effective treatments since various Chinese herbal formulae are used in Asian countries for hepatic and metabolic syndromes (Chen et al, 2006, Hollander and Merchanick 2008).

Objective: To determine whether obesity related NAFLD could be induced in healthy rats by dietary manipulation alone and to investigate the effects of three Chinese herbal formulae in these animals on relevant variables on in vivo measures and on tissue analyses post mortem.

Design: The research comprised of two related studies. Study one was a between subjects equivalent group experiment with repeated measures, with the rats randomly divided among six intervention groups. Five groups were continuously fed a high fat diet (HFD) and one group fed a standard laboratory chow for 11 weeks until sacrifice. Study two entailed the collection of liver and adipose tissues immediately post mortem. These tissue weights were recorded and the livers were used to measure hepatic triglyceride content and for histological examination of the rat liver.

Participants and interventions: 56 male Sprague Dawley rats, six weeks old and weighing between 170 – 210g were randomly divided among six intervention groups. Five groups were continuously fed a HFD and one group, a standard laboratory chow for 11 weeks until sacrifice. After a five week induction period, the six week

intervention phase commenced with the allocated intervention administered daily by oral gavage. Blood collection occurred in the last week before sacrifice for subsequent analyses. The pharmacological interventions comprised Rosiglitazone (RSG); anti-diabetic medication, SK0504 (S4), SK0506 (S6) and a decoction of SK0506 (DS6) as well as water for the two control groups. Note: S4 combines Jiao Gu Lan (*Gynostemma pentaphyllum*), San Qi (*Panax notoginseng*), Huang Lian (*Rhizoma Coptidis*) and Dan Shen (*Salvia miltiorrhiza*) and S6 combines Dan Shen (*Salvia miltiorrhiza*) and Zhi Zi (*Fructus Gardenia Jasminodis*).

Main outcome measures: Bodyweight, food and energy food intake; biochemical and hepatic analyses (plasma glucose, Non-esterified Fatty Acids (NEFA), cholesterol, triglycerides (TG), High Density Lipoprotein-Cholesterol (HDL-C), Alanine Transaminase (ALT), Aspartate Transaminase (AST) and hepatic triglycerides); and histopathological staining (to observe hepatic morphology) were measured.

Results: The results for the five week induction phase suggest that despite the difference in diet (HFD or standard chow) the rats regulated their energy intake as there was no significant difference in the increase in mean weight for the two diets.

During the intervention phase there were further increases in body weight that plateaued after four weeks, quite independent of diet or intervention. However, there was no clear relationship between caloric intake and weight gain in that there were significant differences between the two S6 groups and the others and yet this did not equate to any difference in weight gain.

At the end of the intervention period there was no significant difference between most groups in blood glucose levels and typically animals were within the healthy range. Therefore high fat feeding alone, particularly in a short period of time of ten weeks did not cause hyperglycaemia.

Within the intervention groups there was evidence of marked hyperlipidaemia with the HFD as evidenced by significant increases in NEFA, TG and cholesterol. In general, this was attenuated by the interventions. Notably both forms of the S6 intervention had a cardioprotective effect illustrated by the elevation of levels of HDL-C.

There were potentially hepatotoxic effects indicated by elevation of liver enzymes associated with HFD feeding alone that were supported by histopathological changes in the liver.

Post mortem comparisons included weights of adipose tissues, hepatic tissue and hepatic morphology for evidence of NAFLD. With the epididymal, subcutaneous and inguinal fat deposits, there was a significant degree of fat accumulation in the HFD group compared with the chow group. RSG showed no beneficial effect with regard to fat accumulation, which contrasts with the effects of the two herbal formulae S4 and S6. There was no evidence of hepatomegaly in any group.

High fat feeding resulted in excess hepatic triglyceride levels which was attenuated by RSG, S4 and S6, with S6 being the most effective. Note that no intervention completely prevented this high fat feeding accumulation.

The significant increase in hepatic TG accumulation and plasma biochemical analysis (NEFA, TG and cholesterol) with the high fat feeding in control groups was supported from the histological findings of macro- and microvesicular steatosis fed the HFD alone. These histological changes were absent in animals fed the other HFD based interventions (S6, S4 and RSG). There was no discernable fibrosis in any of the groups.

Conclusion: HFD feeding alone produced NAFLD as hypertriglycercaemia, hypercholesterolaemia and histological evidence of steatosis was observed. The three herbal formulae all attenuated the HFD's hyperlipidaemic effects in relation to plasma TG, NEFA, cholesterol, HDL-C and hepatic TG as no steatosis was formed. However lack of difference in weights between standard chow and HFD fed rats during the induction and intervention phases suggests the model failed to produce obesity which may be due to the short period of 11 weeks of the dietary manipulation.

S4 and S6 both attenuated the effects on liver enzymes of the high fat diet, possibly indicating possible hepatoprotective effects with the values falling towards those for the Chow group. RSG by contrast elevated AST levels above those for HFD.

The two forms of S6; powder and decoction, compared in study one showed generally similar results.

Acknowledgements

This research was made possible through the contribution of many individuals, and the University of Technology, Sydney (Faculty of Science). This research was partially supported by ARC-LP grant #LP0455369. I warmly thank the following individuals for their time and generous contributions throughout the various stages of this degree:

The fifty six Sprague Dawley rats who were my research subjects;

Associate Professor Xianqin Qu for providing the opportunity and funding to conduct the animal experiments;

Yi Tan for her guidance, support and assistance during the animal experiments;

Kathleen Kimpton and Lalit Overlunde for their support and supervision during the animal research;

John Shim and Jane Kim for their support and on-going encouragement;

Dr Mahammund Kamal for his statistical advice and guidance for the enzymatic assay procedures;

Vicky Taylor-Perkins for kindly training me in use of the equipment and arranging access to appropriate histological facilities;

Dr Tamara Sztynka for expertise and advice with respect to histological analysis of the micrographs and proofreading of the histological component of this thesis;

Dr David van Reyk for expert assistance and support in interpreting the biochemical findings;

Dr Michael Johnson, Yean Wang, Phil Laurence, Meggie Leung, Bill Booth and Rochelle Seneviratne for all their solid support, technical advice/ project administration and assistance with the laboratory supplies, equipment and facility access;

My fellow postgraduate students on Level 3 (Room 3.44) and 6 (Room 6.68) for their friendship, advice, support and assistance throughout this degree;

Danny Kim, Estella Choi, Heather Choi, Andy Yang, Caroline Oh, Amy Choi, Janice Lee, Sonia Lee, Joan Kim, Mirah Oh, David Kang, Eric Choi, William Hur, Peace Jeon, Kimberly Son, Pastor Joshua Choi and members of New Life Worship Church, Pastor Edmund Bang of Southern Cross Church and Shuai Zheng for their love, blessings, concern, encouragement and prayer support throughout this degree;

Dorothy Curnow for her kind support, guidance, advice and time in formatting my thesis;

Professor Mark Tennant (Dean of Graduate School) and Professor Greg Skilbeck (Associate Dean of Research, Science) and Dr Deirdre Cobbin for their kind and strong support, advice, guidance especially in the final stages of my thesis submission;

Finally, I would like to thank my parents; Jin Hwa Kim and Kwang Il Kim, my sister Gloria for their trust, faith, encouragement, concern, love and prayer support throughout the hardest and happiest times of my life.

Table of Contents

Abstract	i
Acknowledgements	iv
Table of Contents	vi
Figures	xi
Tables	xv
List of Abbreviations	xvi
Chapter I: Introduction and Aims	1
1.1 Background to the study	1
1.2 Experimental aims	3
1.3 Format of thesis	5
Chapter II: Literature Review	6
2.1 Metabolic Syndrome	6
2.2 Non-alcoholic Fatty Liver Disease (NAFLD)	7
2.2.1 Definition of NAFLD	7
2.2.2 NAFLD in relation to Metabolic Syndrome	7
2.2.3 Incidence and prevalence	8
2.3 Risk factors for NAFLD	9

2.4 Diagnostic procedures and criteria of NAFLD	9
2.4.1 Exclusion criteria	10
2.5 The liver	11
2.5.1 Histological criteria for diagnosis of NAFLD	11
2.4.2 Degree of fibrosis	13
2.4.3 Grading of NAFLD	14
2.4.4 Staging NAFLD	14
2.6 Liver function tests and liver toxicity	14
2.5.1 Alanine Transaminase (ALT)	15
2.5.2 Aspartate Transaminase (AST)	15
2.5.3 Ratio of ALT: AST	15
2.7 Pathogenesis of NAFLD	16
2.7.1 Source of hepatic fatty acids in NAFLD	17
2.8 Animal models	17
2.8.1 Zucker Obese Fatty Rats (ZOF)	18
2.8.2 Wistar Rats (WR)	19
2.8.3 Sprague Dawley Rats (SD)	19
2.9 Treatment for NAFLD	20
2.9.1 Insulin sensitising agents	20
2.8.5 Chinese herbal medicine (CHM)	21
Chapter III: Materials and Methods	24
3.1 Experimental animals and diet	24
3.1.1 Animals	24
3.1.2 Ethics approval	24
3.1.3 Standard diet	25
3.1.4 High Fat Diet (HFD)	25

3.2 Experimental design	26
3.2.1 Introduction	26
3.2.2 Pharmacological interventions	27
3.2.3 Powder form of SK0504 (S4)	29
3.2.4 Powder form of SK0506 (S6)	29
3.2.5 Decoction of SK0506 (DS6)	29
3.2.6 Rosiglitazone (RSG)	30
3.2.7 Collection of blood	30
3.2.8 Collection of liver and tissue samples for Study II	31
3.2.9 Chemicals	31
3.2 In vivo measurements	32
3.3.1. Bodyweight and food intake	32
3.3.2 Body Mass Index (BMI)	32
3.3.3 Glucose concentration and OGTT	33
3.3.4 Triglyceride concentration	33
3.3.5 Non-Esterified Fatty Acid (NEFA) concentration	34
3.3.6 Cholesterol concentration	34
3.3.7 High-Density Lipoprotein Cholesterol (HDL-C) concentration	35
3.4 Analyses of liver enzymes	36
3.4.1 Alanine Transaminase (ALT)	36
3.4.2 Aspartate Transaminase (AST)	37
3.5 Analyses of lipids in liver tissues	38
3.5.1 Hepatic triglyceride concentration	38
3.6 Histological Procedures	38
3.6.1 Tissue preparation	38
3.6.2 Histological staining	39
3.6.3 Haematoxylin and eosin staining	40
3.6.4 Masson's Trichrome (MT) staining	40

3.7 Statistical analyses	41
 Chapter IV: Results for Study I	 42
4.1 Aim I	42
4.1.1. Bodyweight during Induction Phase	42
4.1.2 Food intake during Induction Phase	43
 4.2 Aim II	 44
4.2.1 Bodyweight during Intervention Phase	44
4.2.2 Food and energy intake during Intervention Phase	46
4.2.3 The effects of interventions on BMI	50
4.2.4 The effects of interventions upon NEFA levels	51
4.2.5 The effects of interventions upon triglyceride levels	52
4.2.6 The effects of interventions upon cholesterol levels	53
4.2.7 The effects of interventions upon HDL-C levels	54
4.2.8 The effects of interventions upon glucose metabolism	55
4.2.9 The effects of interventions upon ALT	57
4.2.10 The effects of interventions upon AST	58
4.2.11 The effects of interventions upon ALT: AST Ratio	59
 4.3 Study I Summary	 60
 Chapter V: Study II Results	 62
5.1 Aim III	62
5.1.1 The effects of the interventions in epididymal fat	62
5.1.2 The effects of the interventions in inguinal fat	64
5.1.3 The effects of the interventions in subcutaneous fat	66
5.1.4 The effects of the interventions in the liver weights	68
5.1.5 The effects of the interventions on hepatic triglycerides	69
5.1.6 The effects of the interventions on general liver histology	71
5.1.7 The effects of the interventions on liver stained by Masson's Trichrome stain	72

5.2 Study II Summary	75
 Chapter VI: Discussion and Conclusion	 76
6.1 Discussion	76
6.1.1 Induction Phase	76
6.1.2 Intervention Phase	77
 6.2 Future prospects	 85
 6.3 Conclusion	 87
 References	 89
 Appendices	 102
Appendix I: Diagnostic criteria of Metabolic Syndrome	102
Appendix II: Clinical features of NAFLD	104
Appendix III: Risk factors	106
Appendix IV: Degree of fibrosis	107
Appendix V: Grading and staging of NAFLD	108
Appendix VI: Pathogenesis of NAFLD	109
Appendix VII: Treatment for NAFLD	115
Appendix VIII: Statistical analysis tables	118

Figures

CHAPTER II

Figure 2.1: Disease spectrum of hepatic pathology (Source: Mendez-Sanchez et al, 2007)	7
--	---

Figure 2.2: NAFLD diagnostic flow chart (Choudhury and Sanyal, 2004)	10
--	----

Figure 2.3: Diagram of a “classic” liver lobule (Source: Ross et al, 2003)	12
--	----

Figure 2.4 Diagram of the flow of blood and bile in the liver (Source: Ross et al, 2003)	13
--	----

CHAPTER III

Figure 3.1: Flow chart illustrating Study I design and procedures	28
--	----

CHAPTER IV

Figure 4.1: Bodyweights for the six groups of rats at the beginning (left hand graph) and at the end (right hand graph) of the five week Induction Phase	43
---	----

Figure 4.2: Mean daily food intake (g) per rat of Chow or HFD during the five week Induction Phase	44
--	----

Figure 4.3: Bodyweights for the six groups of rats from week one to five of the Intervention Phase	48
--	----

Figure 4.4a: Food intake during intervention:	49
--	----

Mean daily food intake (g) per rat of Chow, HFD, RSG, S4, S6
and DS6 during Intervention Phase (5 weeks)

Figure 4.4b: Energy intake during intervention: 49

Mean daily energy intake (kJ) per rat for Chow, HFD, RSG, S4, S6
and DS6 groups during Intervention Phase (5 weeks)

Figure 4.5: Mean BMI for Chow, HFD, RSG, S4, S6 50
and DS6 measured in Week 6 of the Intervention Phase

Figure 4.6: Mean fasting plasma NEFA in Chow, HFD, RSG, S4, 51
S6 and DS6 (Day 37 of Intervention Phase)

Figure 4.7: Mean fasting plasma triglycerides in Chow, HFD, 52
RSG, S4, S6 and DS6 on Day 37 of Intervention Phase

Figure 4.8: Mean fasting plasma cholesterol in Chow, HFD, RSG, S4, 53
S6 and DS6 on Day 37 of Intervention Phase

Figure 4.9: Mean fasting plasma HDL-C in Chow, HFD, RSG, S4, 54
S6 and DS6 at Day 37 of the Intervention Phase

Figure 4.10: Mean Fasting plasma glucose in Chow, HFD, RSG, S4, 55
S6 and DS6 at Day 37 of Intervention Phase

Figure 4.11a: OGTT in fasting serum of Chow, HFD, RSG, S4, S6 56
and DS6 measured on Day 37 of the Intervention Phase

Figure 4.11b: Area under the curve (AUC) of serum glucose 56
concentration time profiles of Chow, HFD, RSG, S4, S6
and DS6 at Day 37 of the Intervention Phase

Figure 4.12: Mean fasting plasma Alanine Transaminase (ALT) in 57

Chow, HFD, RSG, S4, S6 and DS6 at Day 37 of Intervention Phase

Figure 4.13: Mean fasting plasma AST in Chow, HFD, RSG, S4, S6 and DS6 on Day 37 of Intervention Phase 58

Figure 4.14: Mean values of ALT:AST Ratio in Chow, HFD, RSG, S4, S6 and DS6 on Day 37 of Intervention Phase 59

CHAPTER V

Figure 5.1: Mean Weights of epidydmal fat in Chow, HFD, RSG, S4 and S6 upon sacrifice 63

Figure 5.1a: Mean ratio of epidydmal fat in Chow, HFD, RSG, S4 and S6 upon sacrifice 64

Figure 5.2: Mean weights of inguinal fat in Chow, HFD, RSG, S4 and S6 upon sacrifice 65

Figure 5.2a: Mean ratio of inguinal fat in Chow, HFD, RSG, S4 and S6 upon sacrifice 66

Figure 5.3: Mean weights of subcutaneous fat in Chow, HFD, RSG, S4, S6 and DS6 upon sacrifice 67

Figure 5.3a: Mean ratio of subcutaneous fat in Chow, HFD, RSG, S4, S6 and DS6 upon sacrifice 68

Figure 5.4: Mean weights of Liver in Chow, HFD, RSG, S4 and S6 groups upon sacrifice 69

Figure 5.5: Measurement of triglyceride content in liver of rat in Chow, HFD, RSG, S4 and S6 upon sacrifice 70

Figure 5.6: Histological assessment of liver morphology 73

The photomicrographs of haematoxylin-eosin stained livers
(magnification x 20) for the five interventions

Figure 5.7: Histological assessment of liver morphology 74

The photomicrographs of Masson's Trichrome stained livers
(magnification x 20) for the five interventions

Tables

CHAPTER III

Table 3.1: The composition and relative proportions of the HFD	25
---	----

Table 3.2: Diet, number, intervention, code and dosage allocated to each group	28
---	----

Table 3.3: Herbal Component of S4, S6 and DS6 with the possible maximum concentration in DS6	30
---	----

CHAPTER IV

Table 4.1 Bodyweights for each week with F and p values for the six groups	45
---	----

Table 4.2 Post hoc Tukey test between the five weeks of intervention for each group	45
--	----

Table 4.3: Summary of results for each of the measurements in Study I	61
--	----

CHAPTER V

Table 5.1: Mean hepatic triglyceride levels and significance level (p) for comparisons between pairs of group means	70
--	----

Table 5.2: Summary of results for each of the measurements in Study II	75
---	----

List of Abbreviations

ACC	Acetyl-CoA carboxylase
AGA	American Gastroenterology Association
ALP	Alkaline Phosphatase
ALT	Alanine Transaminase
AMPK	AMP activated protein kinase
AST	Aspartate Transaminase
ATP	Adult Treatment Panel
BMI	Body Mass Index
CB	endocannabinoid receptor
CHM	Chinese Herbal Medicine
CVD	Cardiovascular Disease
CYP	cytochrome P450
DM	Diabetes Mellitus
DNL	de novo lipogenesis
DS6	Decoction of SK0506
F	Female
FAS	fatty acid synthetase
FFA	Free Fatty Acid
GGT	Gamma Glutamyl Transpeptidase
HCC	Hepatocellular Carcinoma
HDL-C	High Density Lipoprotein- Cholesterol
HFD	High Fat Diet
HNE	hydroxynonenal
HOMA	Homeostasis model assessment
IHCL	intrahepatic content of lipid
IDF	International Diabetes Federation
IL-6	interleukin-6
IR	insulin resistance
IRS	insulin receptor substrate
LDL	Low density Lipoprotein

LR	Liver
LXR- α	liver receptor
MDA	Malondialdehyde
MRI	Magnetic Resonance Imaging
M	Male
MS	Metabolic Syndrome
NAFLD	Non-alcoholic Fatty Liver Disease
NAS	NAFLD Activity Score
NASH	Non Alcoholic Steato-hepatitis
NECP	National Cholesterol Education Program
NEFA	Non Esterified Fatty Acid
OGTT	Oral Glucose Tolerance Test
PMN	polymorphonuclear
PPAR- α	peroxisome proliferators-activated receptors
ROS	reactive oxygen species
RSG	Rosiglitazone
S4	SK0504
S6	SK0506
SD	Sprague Dawley
SGOT	Serum Glutamic Oxaloacetic Transaminase
SGPT	Serum Glutamic Pyruvic Transaminase
SOCS	suppressor of cytokine signalling
SP	Spleen
SREBP	Sterol-regulatory element-binding protein
TG	Triglycerides
TNF- α	Tumour Necrosis Factor Alpha
TCM	Traditional Chinese Medicine
TZD	thiazolidinedione
UDCA	Ursodeoxycholic acid
VLDL	Very Low Density Lipoprotein
WHO	World Health Organisation
WR	Wistar Rat
ZOF	Zucker Obese Fatty
